The invention belongs to the technical field of biological
medicine, and particularly relates to the field of
gene therapy and
pain therapy. The invention provides an sgRNA and AAV-CRISPRi
virus system for targeted inhibition of TRPV1
gene, the AAV-CRISPRi
virus system is a CRISPRi
system based on AAV delivery, and the core functional structure sequence of the AAV-CRISPRi
virus system is a 5 '-ITR inverted
repeat sequence, an EF1 alpha core
promoter, a ZIM3 transcription inhibition structural domain, a
linker, a sadCas9-NLS nuclear localization
signal-SV40 poly (A) termination
signal-U6
promoter, and an sgRNA-3'-ITR inverted
repeat sequence, according to the core functional structure, the
miniaturization of a CRISPRi system is realized, and the infection success rate and the
target gene inhibition efficiency are improved while the
plasmid construction and AAV packaging costs are reduced. The AAV-CRISPRi virus system for targeted inhibition of the TRPV1
gene is used for preparing drugs for
chronic pain, and has the characteristics of high efficiency, strong specificity and few side effects.